Growth Metrics

Edwards Lifesciences (EW) Cost of Revenue (2016 - 2026)

Edwards Lifesciences has reported Cost of Revenue over the past 17 years, most recently at $343.0 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 17.39% year-over-year to $343.0 million; the TTM value through Dec 2025 reached $1.3 billion, up 19.39%, while the annual FY2025 figure was $1.3 billion, 19.39% up from the prior year.
  • Cost of Revenue for Q4 2025 was $343.0 million at Edwards Lifesciences, down from $345.2 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $345.2 million in Q3 2025 and troughed at -$98.8 million in Q4 2022.
  • A 5-year average of $275.6 million and a median of $292.8 million in 2021 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: crashed 131.92% in 2022 and later surged 354.05% in 2023.
  • Year by year, Cost of Revenue stood at $309.5 million in 2021, then crashed by 131.92% to -$98.8 million in 2022, then soared by 354.05% to $251.0 million in 2023, then increased by 16.41% to $292.2 million in 2024, then increased by 17.39% to $343.0 million in 2025.
  • Business Quant data shows Cost of Revenue for EW at $343.0 million in Q4 2025, $345.2 million in Q3 2025, and $344.4 million in Q2 2025.